XBiotech Inc. (NASDAQ:XBIT - Get Free Report) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.88 and traded as low as $2.80. XBiotech shares last traded at $3.08, with a volume of 44,965 shares trading hands.
XBiotech Stock Up 1.1%
The stock has a market cap of $87.51 million, a P/E ratio of -2.22 and a beta of 0.98. The firm's 50-day moving average is $2.88 and its two-hundred day moving average is $3.12.
XBiotech (NASDAQ:XBIT - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) EPS for the quarter.
Hedge Funds Weigh In On XBiotech
Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,930 shares during the period. Virtu Financial LLC bought a new position in shares of XBiotech in the fourth quarter valued at approximately $58,000. Hsbc Holdings PLC bought a new position in shares of XBiotech in the first quarter valued at approximately $52,000. Bank of America Corp DE grew its stake in shares of XBiotech by 42.0% in the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock worth $79,000 after acquiring an additional 5,887 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of XBiotech in the first quarter worth $81,000. Institutional investors own 55.70% of the company's stock.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Recommended Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access